Biotech

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. (NYSE:ABBV), on Thursday, announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform...

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s (NASDAQ:MRNA) supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease. The...

Shares of Klotho Neurosciences, Inc. (NASDAQ:KLTO) have soared more than 1000% over the past three months on promising results and breakthrough hopes. Klotho stock was in the spotlight again Thursday after announcing an FDA nod on its ALS treatment candidate.  What's Driving The Rally: ...

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Mereo BioPharma Group plc (NASDAQ:MREO) stocks are plunging on Thursday. What Happened? The companies on Wednesday announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and...

Pelthos Therapeutics Inc. (NYSE:PTHS) on Thursday announced the launch of Zelsuvmi (berdazimer) topical gel 10.3% for molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older. Zelsuvmi received a Novel Drug designation from the U.S. Food and Drug Administration...

IGC Pharma Inc (NYSE:IGC) witnessed a surge of 69.40%  in its stock value during after-hours trading on Wednesday. What Happened: The stock of IGC Pharma, a company involved in the development of cannabinoid-based therapies for Alzheimer‘s disease, rose by 69.40% to $0.62. This surge...

Eli Lilly and Co. (NYSE:LLY) is set to release its second-quarter earnings on August 7. According to Benzinga Pro data, analysts are anticipating adjusted earnings of $5.56 per share and sales of $14.4 billion. Expectations are slightly higher for the quarter, primarily driven by the...

Kazia Therapeutics (NASDAQ:KZIA) on Wednesday reported preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab), and standard chemotherapy after completing Cycle 1 (21 days) of...

Johnson & Johnson (NYSE:JNJ) is set to release its second-quarter earnings on Wednesday, July 16. According to Benzinga Pro data, analysts estimate adjusted earnings of $2.68 per share and sales of $22.85 billion. While overall estimates for 2025 and beyond show only slight increases, investor...

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) on Wednesday released topline results from its Phase 2 trial evaluating bivamelagon (formerly LB54640), an investigational oral melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity. Hypothalamic obesity is a rare type of...

Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir — Gilead’s twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as pre-exposure prophylaxis (...

The U.S. Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for Eli Lilly and Co.’s (NYSE:LLY) Kisunla (donanemab-azbt) once-monthly amyloid-targeting therapy for adults with early symptomatic Alzheimer’s disease (AD). The FDA...

Merck & Co. Inc. (NYSE:MRK) agreed on Wednesday to acquire Verona Pharma plc (NASDAQ:VRNA) for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. Each ADS represents eight ordinary shares of Verona Pharma. Through the acquisition of this...

RxSight Inc. (NASDAQ:RXST) plummeted by 34.32% in after-hours trading on Tuesday. The drop followed the company’s decision to revise its 2025 revenue forecast. What Happened: The stock of RxSight Inc. experienced a sharp decline in after-hours trading, closing at $8.40, a 34.32% decrease from...

Calidi Biotherapeutics Inc. (NYSE:CLDI) stock surged by 39.47% in the after-hours trading session on Tuesday. The stock price increased by $0.095, reaching $0.34. The company’s stock had closed at $0.24 on the same day. What Happened: The stock’s after-hours surge comes on the heels of...